## Total Synthesis of (+)-*erythro-N*-Lauroyldocosasphinga-4,8-dienine from *Anemonia sulcata* and Determination of the Absolute Configuration

## Masako Nakagawa,\* Akihiko Tsuruoka, Jun Yoshida, and Tohru Hino\*

Faculty of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Chiba, 260, Japan

A new sphingosine derivative (1) from Anemonia sulcata has been synthesized and the L-erythro configuration determined.

Several reports of the occurrence of the dienic long-chain base, sphingadienine, have appeared in recent years.<sup>1</sup> A new sphingosine derivative, *erythro*-docosasphinga-4,8-dienine, has recently been isolated and characterized as an N-lauroyl derivative from Anemonia sulcata collected near Sousse; its

structure was reported to be (1).<sup>2</sup> However, the absolute configuration of (1) has not been determined yet, although the relative stereochemistry at C-2 and C-3 has been determined to be *erythro* by the coupling constants between H-2 and H-3. We have reported a simple method for preparation of

(2) OH OH NO2 Ň٥ Me[CH2]10 ö (5) (3) (4) OR<sup>2</sup> OH OB. Me[CH<sub>2</sub>]10 Me[CH<sub>2</sub>]<sub>10</sub> Me[CH<sub>2</sub>]<sub>10</sub> (7)  $R^1 = CPh_3$ ,  $R^2 = COCH(OMe)Ph$ COCH(OMe)Ph (+)-(1) B<sup>1</sup> +)-(1) R<sup>1</sup> = H, R<sup>2</sup> = H  $X = Me[CH_2]_{12}$ 

Scheme 1. Reagents and conditions: i, HO[CH<sub>2</sub>]<sub>2</sub>NO<sub>2</sub> (3.5 equiv.), Et<sub>3</sub>N, 4°C, 4 days; ii, Me<sub>2</sub>C(OMe)<sub>2</sub>-acetone, PPTS (0.1 equiv.), reflux, 16 h; iii, Et<sub>3</sub>N, reflux, 5 h; iv, Al-Hg, tetrahydrofuran (THF)-H<sub>2</sub>O, room temp., 1 h; v, Me[CH<sub>2</sub>]<sub>10</sub>COCl (1 equiv.), Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 12 h; vi, pyridinium toluene-*p*-sulphonate (PPTS) (1.0 equiv.), MeOH, room temp., 2 days; vii, Ph<sub>3</sub>CCl (2 equiv.), dimethylaminopyridine (DMAP) (3 quiv.), pyridine, 100 °C, 1.5 h; viii, (S)-O-methylmandelyl chloride, pyridine, benzene, room temp., 40 min, separation; ix, *p*-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H (1.3 equiv.), MeOH, room temp.; x, MeONa (4 equiv.), MeOH, room temp.



Scheme 2. Reagents and conditions: i,  $Bu^{n}_{2}BOSO_{2}CF_{3}$  (1.1 equiv.),  $Et_{3}N$  (1.4 equiv.),  $Et_{2}O$ ,  $-78^{\circ}C$ , then room temp., 1.5 h; ii, (2),  $-78^{\circ}C$ , 30 min, then  $0^{\circ}C$ , 2 h; iii, NaN<sub>3</sub> (2 equiv.), dimethylformamide (DMF), room temp., 2.5 h; iv, MeOMgBr (1.1 equiv.), MeOH,  $0^{\circ}C$ , 5 min; v, LiAlH<sub>4</sub> (3 equiv.),  $Et_{2}O$ ,  $0^{\circ}C$ , 15 min, then room temp., 1 h; vi, camphorsulphonic acid (CSA; 1 equiv.),  $Me_{2}C(OMe)_{2}$ , reflux, 1 h.



Scheme 3. Reagents and conditions: i, THF, -23 °C, 1.5 h; ii, p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H (0.1 equiv.), MeOH, room temp., 6.5 h; iii, conc. HCl, AcOEt, room temp., 50 min; iv, LiAlH<sub>4</sub> (excess), MeO[CH<sub>2</sub>]<sub>2</sub>OMe, reflux, 10 h; v, Me<sub>2</sub>C(OMe)<sub>2</sub>, CSA (1 equiv.), reflux, 1 h.

*erythro*-sphingosine<sup>3</sup> which was applied to the total synthesis of cerebroside  $B_{1b}$ .<sup>4</sup> We now report the total synthesis of (1) by three different approaches and the determination of its absolute configuration.

The first approach to (1) involved the optical resolution of the racemic erythro-ceramide  $(\pm)$ -(1), obtained by our method which included the 1,2-addition reaction of nitroethanol to the dienal (2)<sup>3,4</sup> (Scheme 1). Treatment of the dienal (2) with nitroethanol gave the nitrodiol  $(\pm)$ -(3) (71%) as a mixture of erythro- and threo-isomers which was converted to the erythro-acetonide  $(\pm)$ -(4) [66% from (3)]. Reduction of  $(\pm)$ -(4), followed by acylation with lauroyl chloride, gave  $(\pm)$ -(5). Deprotection of  $(\pm)$ -(5) provided the erythro-N-lauroyldocosasphinga-4,8-dienine  $(\pm)$ -(1), m.p. 75.5 °C [54% from (4)].

Tritylation of  $(\pm)$ -(1), followed by esterification with (S)-O-methylmandelyl chloride<sup>5</sup> afforded a mixture of diastereoisomers (7) and (8),† separable by column chromato-

graphy. Detritylation and hydrolysis of the mandelates (7) and (8) afforded the corresponding enantiomeric alcohols (+)-(1) {m.p. 79.0-80.5 °C;  $[\alpha]_D$  +2.25° (*c* 0.844, CHCl<sub>3</sub>); 18% from (±)-(1)} and (-)-(1) {m.p. 79.0-82.0 °C;  $[\alpha]_D$  -2.47° (*c* 1.094, CHCl<sub>3</sub>); 14% from (±)-(1)},‡ respectively. The spectral data (IR, NMR, mass) of the synthetic (+)-(1) and (-)-(1) were identical with those of the natural product (lit. m.p. reported<sup>2</sup> as 297-298 °C; the m.p. of the natural products kindly given by Dr. Guyot was ~74 °C in our hands).

With the optically active (1) thus available by resolution, we then attempted two different chiral syntheses of (-)-(1) by unequivocal methods in order to determine the absolute configuration of the natural product (+)-(1).

The first approach involved the stereoselective aldol addi-

<sup>&</sup>lt;sup>†</sup> The absolute configuration of the O-methylmandelate esters (7)  $[\delta_H 3.45 (2-H) \text{ and } 5.42 (4-H)] \text{ and } (8) [\delta_H 3.41 (2-H) \text{ and } 5.43 (4-H)]$  was estimated to be (2*R*,3*S*) and (2*S*,3*R*), respectively.<sup>5</sup>

<sup>‡ (-)-(1):</sup>  $v_{max}$ .(KBr) 3280, 1635, and 960 cm<sup>-1</sup>;  $\delta_{\rm H}$  5.78 (1H, m, 5-H), 5.55 (1H, dd, J 15.4 and 6.3 Hz, 4-H), 5.45—5.34 (2H, m, 8- and 9-H), 4.32 (1H, m, 3-H), 3.95 (1H, dt, J 11.3 and 3.9 Hz, 1-H), 3.91 (1H, m, 2-H), 3.70 (1H, ddd, J 11, 7.7, and 3.3 Hz, 1-H), 2.73 (1H, d, J 5.0 Hz, CHOH, exch.), and 2.68 (1H, dd, J 7.4 and 3.9 Hz, CH<sub>2</sub>OH, exch.); *m/z* 535 (0.76, *M*<sup>+</sup>), 517 (2.09, *M*<sup>+</sup> – H<sub>2</sub>O), 225 (52.19), and 60 (100%); satisfactory elemental analyses were obtained.

tion of (2) with Evans' chiral haloacetate enolate,<sup>6</sup> prepared from the bromoacetyloxazolidin-2-one (9), di-n-butylboryl trifluoromethanesulphonate (1.1 equiv.), and Et<sub>3</sub>N, which afforded the bromo aldol adduct (10) {89%,  $[\alpha]_D + 43^\circ$  (*c* 1.025, CHCl<sub>3</sub>)} with >92% diastereoisomeric purity. Treatment of (10) with sodium azide in dimethylformamide (DMF) gave the corresponding azide (11) (99%). Methanolysis of (11) with methoxymagnesium bromide afforded the enantiomerically pure  $\alpha$ -azido ester (12) (70%). LiAlH<sub>4</sub> reduction of (12) gave sphingadienine (13) which was immediately converted to the acetonide (14) [31% from (12)]. Acylation of (14) with lauroyl chloride yielded the *N*-lauroyl derivative (5) (95%), which was deprotected to give (2*S*,3*R*)-(-)-(1) {93%, m.p. 80–81.5 °C,  $[\alpha]_D - 3.20^\circ$  (*c* 1.769, CHCl<sub>3</sub>)} (Scheme 2).

In order rigorously to confirm the stereochemistry of (-)-(1), another approach to (-)-(1) by a stereoselective synthesis from L-serine<sup>7</sup> was carried out (Scheme 3). Reaction of the protected L-serinal (16) with nonadec-5-en-1-ynyl-lithium (15) provided the *erythro*-alkynol (17) {47%,  $[\alpha]_D$  - 38.1° (c 1.000, CHCl<sub>3</sub>)} together with the *threo*-isomer (2%). Treatment of (17) with p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H in MeOH resulted in selective cleavage of the acetal moiety, leading to the 1,3-diol (18). Acid hydrolysis of (18) to give (19) followed by selective LiAlH<sub>4</sub> reduction<sup>8</sup> gave (13) which was converted to (14) without purification. Acylation of (14) followed by deprotection gave the crystalline (2S,3R)-(-)-(1) {m.p. 78-80 °C,  $[\alpha]_D - 3.47^\circ$  (c 0.336, CHCl<sub>3</sub>); lit.<sup>2</sup> m.p. 297-298 °C,  $[\alpha]_D + 2.94^\circ$  (CHCl<sub>3</sub>)}.

Compound (1) was unambiguously shown by <sup>1</sup>H NMR analysis of (14) to have the *erythro*-relative configuration.

Since the natural product (1) has been reported to have a positive optical rotation  $\{[\alpha]_D + 2.94^\circ (CHCl_3)\}$ ; the present synthesis allows the absolute configuration of the natural product to be assigned as L-erythro [(2R,3S)-(+)-erythro-N-lauroyldocosasphinga-4,8-dienine].

We thank Dr. Guyot, Musée National d'Histoire Naturelle, for a generous gift of the natural product. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan. We are also grateful to the Japan Foundation for Optically Active Compounds.

Received, 28th November 1989; Com. 9/05085J

## References

- 1 K.-A. Karlsson, in 'Biological Membranes,' ed. D. Chapman, Academic Press, London, 1982, vol. 4, p. 1.
- 2 K. Chebaane and M. Guyot, Tetrahedron Lett., 1986, 27, 1495.
- 3 T. Hino, K. Nakayama, M. Taniguchi, and M. Nakagawa, J. Chem. Soc., Perkin Trans. 1, 1986, 1687.
- 4 M. Nakagawa, S. Kodato, K. Nakayama, and T. Hino, *Tetrahedron* Lett., 1987, 28, 6281.
- 5 B. M. Trost, J. L. Belletire, S. Godleski, P. G. McDougal, J. M. Balkovec, J. J. Baldwin, M. E. Christy, G. S. Ponticello, S. L. Varga, and J. P. Springer, *J. Org. Chem.*, 1986, **51**, 2370.
- 6 D. A. Evans, E. B. Sjogren, A. E. Weber, and R. E. Conn, Tetrahedron Lett., 1987, 28, 39.
- 7 S. Nimkar, D. Menaldino, A. H. Merrill, and D. Liotta, *Tetrahedron Lett.*, 1988, 29, 3037; H.-E. Radunz, R. M. Devant, and V. Eiermann, *Liebigs Ann. Chem.*, 1988, 1103.
- 8 W. T. Borden, J. Am. Chem. Soc., 1970, 92, 4898.